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Abstract
Evidence of the potential beneﬁts of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of
liver disease is limited.
Patients who were diagnosed with liver cirrhosis with a Child–Pugh (CP) score of 8–10 were included. The BCAA group consumed
BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on
the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival
over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA
group was divided into 3 subgroups, whose patients consumed 4.15g, 8.3g, or 12.45g of BCAAs daily for the analysis. There were
signiﬁcant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the
propensity scores, we analyzed patients in the BCAA-12.45g group (12.45g of BCAAs daily, n=41) andmatched control group (n=
41). The MELD score signiﬁcantly improved in the BCCA-12.45g group compared to the matched control group (P= .004). The
changes in the serum bilirubin level (P= .014) and CP score (P= .033) over time also differed signiﬁcantly between the 2 groups. The
incidence rates of cirrhosis-related complications (P= .973) and development of hepatocellular carcinoma (2 cases each) did not
differ signiﬁcantly between the 2 groups.
Long-term oral BCAA supplementation has beneﬁcial effects in patients with advanced liver cirrhosis. A further large-scale
prospective study is needed to delineate these beneﬁcial effects.
Abbreviations: BCAAs = branched-chain amino acids, BMI = body mass index, CHB = chronic hepatitis B, CHC = chronic
hepatitis C, CP = Child–Pugh, EFS = event-free survival, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, MELD =model
for end-stage liver disease.
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The progression of chronic liver disease results in diminished
hepatic glycogen stores due to a catabolic state that requires a
higher protein intake than usual.[1,2] The negative nitrogen balance
is exaggerated, especially in advanced liver disease, due to disease-
associated factors including low protein intake and anorexia.[3,4]
As a result, protein-calorie malnutrition, which is a body wasting
condition caused by a dietary shortage in calories and protein, in
advanced liver disease increases the risks of complications and
death.[3] Approximately two-thirds of patients with advanced liver
disease and almost all patients waiting for liver transplantation are
subject to this condition.[5] Regardless of any etiology, including
alcoholic or nonalcoholic and cholestatic or noncholestatic liver
disease, malnutrition can develop in patients with chronic liver
disease.[6] Early screening of nutritional status and intervention in
patients with chronic liver disease can reduce their risks of
complications.[7]However, there are limiteddata related topatients
with chronic liver disease requiring nutritional intervention.[8]
Branched-chain amino acids (BCAAs) are a preferential source
of nitrogen for glutamate synthesis, which detoxify ammonia in
the skeletal muscle as well as represent an essential substrate for
the synthesis of body proteins.[9] The beneﬁcial effects of BCAAs
on protein metabolism and the nutritional state of patients with
chronic liver disease are well known.[10,11] In the progression of
liver cirrhosis, the depletion of BCCAs, such as leucine,
isoleucine, and valine inhibits protein synthesis and protein
turnover.[1,12] Moreover, the skeletal muscle catabolizes BCAAs
more rapidly than most other amino acids,[13,14] and these
increase the major complications of liver cirrhosis during disease
progression: hepatic encephalopathy, edema, and ascites accom-
panied by hypoalbuminemia, insulin resistance, hepatocarcino-
genesis, and infection caused by an impaired immune
function.[9,15,16] Furthermore, a lower serum BCAA/aromatic-
amino-acid ratio is associated with a worse prognosis in patients
with advanced liver disease.[17] However, there is still little
consensus on the optimal dose and duration of BCAA
supplementation for chronic liver disease.
The present study investigated the long-term effectiveness of
oral BCCA supplementation by analyzing the model for end-
stage liver disease (MELD) score and the occurrence of
complications in advanced liver disease.2. Methods
2.1. Eligible patients
The eligibility criteria applied in this study were as follows: (1)
diagnosis of liver cirrhosis documented by histology or imagingFigure 1. Scheme of
2ﬁndings and conﬁrmed by laboratory data, (2) Child–Pugh (CP)
score between 8 and 10, and (3) age 18–80 years. The exclusion
criteria were as follows: (1) diagnosis of malignancy (except
hepatocellular carcinoma [HCC]) within the past 3 years or the
presence of an untreated malignancy, (2) failure of a major organ,
such as the heart, lung, or kidney, (3) being admitted or receiving
medical therapy, or dialysis, (4) on a waiting list or under
consideration for a major organ transplantation, (5) serum
creatinine level higher than 1.5 mg/dL, (6) receiving treatment
with albumin replacement regularly, (7) presence of a viableHCC
tumor, advanced Barcelona Clinic Liver Cancer stage, or HCC
with a life expectancy of less than 6 months, (8) persistence of
alcohol consumption, (9) amyotrophic lateral sclerosis, (10)
presence of another metabolic disorder presenting branched-
chain ketoaciduria, (11) inability to calculate the MELD score at
the time of enrollment, (12) transient impairment of liver
function, or (13) treatment with a medication that affects the
prothrombin time (e.g., warfarin).2.2. Study design
This study had a multicenter, retrospective, observational, cohort
design and involved 13 tertiary medical centers in South Korea.
Each center was asked to recruit all patients with advanced liver
cirrhosis of any etiology between January 1, 2008, and December
31,2010.Thestudyprotocol ispresented inFig.1.Afterenrollment,
the patients were divided into 2 groups: treated or not treated with
BCAAs.TheBCAAgroup consumed anydose of BCAAsdaily, and
the control group consumed a diet without BCAA for at least 6
months.After6months,weanalyzed thedata in these2groupsover
2 years, including the duration of BCAA medication.
The primary end point of the study was the changes in the
MELD score over time. The secondary end point was the changes
in the CP score, incidence of HCC, survival, development of liver
cirrhosis-related complications, including the development or
aggravation of ascites, spontaneous bacterial peritonitis, hepatic
encephalopathy, rupture of esophageal or gastric varices,
hepatorenal syndrome, and development or recurrence of
HCC. This study was exempt from the requirement in written
informed consent because the data were analyzed anonymously.
This study was approved by the institutional review board
(KNUH 2012-10-024) of each center and was conducted in
accordance with the principles of the Declaration of Helsinki.2.3. Baseline assessments and follow-up
We initially performed a liver function test and evaluated the
serum creatinine, viral markers of hepatitis B virus (HBV) andthe study design.
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and history of cirrhotic complications, including HCC. The
follow-up examinations included laboratory studies, including
the serum total bilirubin, albumin, and creatinine; prothrombin
activity; prognostic markers, including the CP score and MELD
score; and any complications, including HCC and death.2.4. BCAA content and compliance with BCAA treatment
Patients in the BCAA group were treated with a nutritional
preparation (LIVACT, Samil Pharmaceutical Co., Ltd., Seoul,
Korea; 4.15g of BCAA granules per sachet containing 952mg of
L-iso-leucine, 1904 mg of L-leucine, and 1144mg of L-valine).
The BCAA group was divided into 3 subgroups, whose patients
consumed 4.15g, 8.3g, or 12.45g of BCAA granules daily. More
than 80% of the patients complied with their prescribed intake of
BCAA granules. Patients in the control group consumed a
standard diet without BCAAs.2.5. Statistical analysis
Data were analyzed using the IBM SPSS 20.0 (IBMCo., Armonk,
NY). Baseline characteristics were compared between the 2 study
groups using the chi-square test, Student’s t-test, or linear-by-
linear association test. Changes in theMELD score, CP score, and
serum albumin between the 2 groups were analyzed using a
mixed linear model. The incidence of cirrhotic complications was
compared using the chi-square test. The cumulative survival and
event-free survival (EFS) rates were estimated using the Kaplan–-
Meier method and compared using the log-rank test. Patients
were counted at the loss of follow-up or death of any cause.
Factors related to the incidence of HCC were analyzed using the
Cox proportional-hazards model. A probability value of P<0.05
was considered to indicate a statistical signiﬁcance.Figure 2. Flow diag
33. Results
A retrospective analysis was applied to 867 patients who met the
inclusion criteria, of which 552 were excluded. The main reasons
for exclusion were the presence of a viable or advanced HCC,
abnormal serum creatinine level, and inability to cease alcohol
consumption. Among the 315 patients, 8 patients who received
medication less frequently than once a day were excluded from
the analysis. Finally, a total of 307 patients (166 in the BCAA
group, 141 in the control group) were analyzed (Fig. 2).
There were signiﬁcant differences between the BCAA and
control groups in the distribution of the CP score, serum albumin
level, and hepatic encephalopathy (Table 1). We attributed these
differences to the physicians tending to prescribe BCAAs to
patients with greater deterioration of the hepatic reservoir.3.1. Analysis of the propensity scores
In observational studies, and especially retrospective studies, the
presence of a selection bias often confuses the treatment
effects.[18,19] The propensity score relates to the probability of
a patient receiving a speciﬁc treatment.[20] A quasi-randomized
experiment can be conducted by matching the results with the
propensity scores to yield an adjusted estimate of the treatment
effect.[21] A logistic regression model with the covariates of sex,
age, presence of varices, history of HCC, CP score, and MELD
score was used to estimate the propensity scores for the BCAAs.
Matching the patients who were treated with 12.45g of BCAAs
daily (n=41) on a one-to-one basis with those in the control
group resulted in the closest propensity scores. The baseline
characteristics in the 2 groups are listed in Table 2. The mean
follow-up duration did not differ signiﬁcantly between the 2
groups (17.5±6.5 months in the BCAA-12.45g group and 17.5
±6.7 months in the matched control group, P= .854).ram of the study.
Table 1
Baseline characteristics between control and any dose of BCAAs treated group.
Characteristic Control BCAA, any dose P
Number of patients 141 166 –
Male, n, % 93 (66%) 109 (66%) 0.957
Age, y, mean ± SD 59±11 60±9 0.742
BMI, kg/m2, mean ± SD 23.3±3.8 24.3±4.6 0.088
Etiology HBV/HCV/alcohol/others, n 63/12/49/17 67/27/57/15 0.202
Child–Pugh score 8/9/10, n 89/34/18 77/49/40 0.002
∗
MELD, mean±SD 13.7±3.2 13.9±33 0.605
Serum albumin, g/dL, mean±SD 3.0±0.5 2.8±0.4 0.002
∗
Total bilirubin, mg/dL, mean±SD 3.1±3.1 3.0±2.7 0.603
Serum creatinine, mg/dL 0.82±0.24 0.82±0.24 0.832
INR, mean±SD 1.40±0.27 1.38±0.29 0.829
Platelet count,109/L, mean±SD 87±49 86±45 0.831
Presence of varices, n, % 17 (12%) 32 (19%) 0.085
Hepatic encephalopathy none/grade 1–2/grade 3–4, n 131/10/0 135/31/0 0.003
∗
Ascites none/mild/moderate to severe, n 34/82/25 36/85/45 0.128
History of HCC, n, % 42 (30%) 46 (28%) 0.688
BCAA=branched-chain amino acid, BMI=body mass index, HBV=hepatitis B virus, HCV=hepatitis C virus, INR= international normalized ratio, HCC=hepatocellular carcinoma, MELD=Model for End-Stage
Liver Disease.
∗
P value < 0.05.
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Figure 3A shows the changes in the MELD scores over 2 years in
the 2 study groups. The MELD scores improved signiﬁcantly in
the BCAA-12.45g group over time (P= .004). Figure 3B–D
shows the changes in the CP score, serum albumin level, and
bilirubin level, respectively, over 2 years in the 2 groups. The
serum bilirubin level (P= .014) and CP score (P= .033) also
improved signiﬁcantly between the 2 groups over time. However,
there was no signiﬁcant intergroup difference in the serum
albumin level (P= .751). The subgroup analyses revealed
improvements in the MELD score and serum bilirubin level in
patients treated with 8.3g of BCAAs, whereas only improve-
ments in the serum bilirubin level were observed in the patients
treated with 4.15g of BCAAs (Table 3).Table 2
Baseline characteristic between 12.45g of BCAAs treated group and u
Characteristic BCAA-12.45 g
Number of patients 41
Male, n, % 32 (78%)
Age, y, mean±SD 59±9
BMI, kg/m2, mean±SD 24.7±6.4
Etiology HBV/HCV/alcohol/others, n 17/7/14/3
Child–Pugh score 8/9/10, n 16/15/10
MELD, mean±SD 13.8±4.0
Serum albumin, g/dL, mean±SD 2.8±0.4
Total bilirubin, mg/dL, mean±SD 3.4±3.5
Serum creatinine, mg/dL 0.81±0.22
INR, mean±SD 1.38±0.29
Platelet count,109/L, mean±SD 84±50
Presence of varices, n, % 9 (22%)
Hepatic encephalopathy none/grade 1–2/grade 3–4, n 34/7/0
Ascites none/mild/moderate to severe, n 8/17/16
History of HCC, n, % 12 (29%)
BCAAs=branched-chain amino acids, BMI=body mass index, HBV=hepatitis B virus, HCC=hepatocel
stage liver disease.
∗
P value < 0.05.
43.3. Major cirrhotic complications and survival
The cumulative EFS curves for both study groups are shown in
Fig. 4. There was no signiﬁcant intergroup difference in the EFS
(19.3±1.2 months [mean±SD] in the BCAA-12.45g group and
19.2±1.2 months in the matched control group, P= .973).
Table 4 lists the major cirrhotic complications in both groups.
The total events of cirrhotic complications did not differ
signiﬁcantly between the 2 groups (P= .814). There were also
no signiﬁcant intergroup differences in the following speciﬁc
complications: development or aggravation of ascites, hepatic
encephalopathy, hepatorenal syndrome, rupture of varices,
spontaneous bacterial peritonitis, or death. HCC occurred in
only 1 patient in the matched control group and 2 patients in the
BCAA-12.45g group. The cumulative HCC recurrence rate didnmatched control, or matched control using the propensity score.
Unmatched control P Matched control P
141 – 41 –
93 (66%) 0.142 30 (73%) 0.607
59±11 0.991 59±12 0.819
22.8±3.6 0.055 22.6±3.3 0.188
63/12/49/17 0.726 21/5/12/3 0.823
89/34/18 0.007
∗
14/14/13 0.492
13.8±3.2 0.974 14.4±2.8 0.471
3.0±0.4 0.059 2.9±0.4 0.297
3.0±2.5 0.512 3.1±2.3 0.652
0.82±0.25 0.845 0.78±0.23 0.515
1.39±0.25 0.840 1.48±0.29 0.128
84±43 0.977 82±38 0.820
17 (12%) 0.111 9 (22%) 1.000
131/10/0 0.053 37/4/0 0.331
34/82/25 0.031
∗
9/20/12 0.451
42 (30%) 0.949 8 (20%) 0.304
lular carcinoma, HCV=hepatitis C virus, INR= international normalized ratio, MEDL=model for end-
Figure 3. Changes in the MELD (A) and Child–Pugh (B) scores, serum albumin (C), and total bilirubin (D) in the 12.45g branched-chain amino acid-treated group
and matched control group over 2 years. MELD=model for end-stage liver disease.
Park et al. Medicine (2017) 96:24 www.md-journal.comnot signiﬁcantly differ between the 2 groups (P= .271, hazard
ratio=0.179; 95% conﬁdence interval=0.008–3.841).4. Discussion
An exogenous protein supply was known to accelerate protein
synthesis as well as inhibit proteolysis.[21,22] BCAAs, including
valine, leucine, and isoleucine are indispensable amino acids and
have been shown to be effective in proteolytic illnesses, such as
sepsis, cancer, and trauma.[23,24] Early studies on the effectivenessTable 3
Changes of serum albumin, total bilirubin, and prognostic marker do
MELD score Child–Pu
BCAA, 4.15g, P value 0.151 1.0
BCAA, 8.3g 0.006
∗
0.0
BCAA, 12.45 g 0.004
∗
0.03
BCAA, above 8.3 g 0.032
∗
0.8
BCAAs=branched-chain amino acids, MELD=model for end-stage liver disease.
† The changes in all values were analyzed using the linear mixed model after one-to-one matching eac
∗
P value < 0.05.
5of BCAA supplementation in patients with chronic liver disease
focused on malnutrition and encephalopathy.[8,25] Many clinical
trials have demonstrated the beneﬁcial effects of BCAAs in
patients with hepatic encephalopathy.[10,25–27] The progression
of chronic liver disease is associated with the metabolism of
amino acids resulting in a decreased circulating BCAA/aromatic-
amino-acid ratio.[28,29] This alteration may induce hepatic
encephalopathy due to elevated ammonia levels in the serum
and brain.[30] There is evidence of the beneﬁcial role of BCAAs
in hepatic encephalopathy, although there are also conﬂictingsages of BCAAs†.
gh score Serum albumin Total bilirubin
00 0.330 0.025
∗
79 0.403 0.001
∗
3
∗
0.751 0.014
∗
22 0.514 0.000
∗
h dose of BCAA-treated group with control using the propensity score.
[10,26,31]
Table 4
The major cirrhotic complications in 12.45g of BCAAs-treated
group and matched control group.
Event Matched
control
BCAA
-12.45 g
P
Number of patients 47 47 –
Total events except HCC, n, % 14 (41) 13 (41) 0.814
Rupture of varices, n, % 3 (7) 9 (22) 0.061
Development or aggravation of ascites, n, % 9 (22) 10 (24) 0.794
Hepatorenal syndrome, n, % 2 (5) 4 (10) 0.396
Hepatic encephalopathy, n, % 4 (10) 5 (12) 0.724
Spontaneous bacterial peritonitis, n, % 2 (4) 1 (2) 0.556
Development of HCC, n, % 1 (3) 2 (6) 0.573
Recurrence of HCC, n, % 6 (60) 2 (22) 0.096
Death, n, % 6 (15) 6 (15) 1.000
BCAAs=branched-chain amino acids, HCC = hepatocellular carcinoma.
Figure 4. Cumulative event-free survival in the 12.45g branched-chain amino
acid-treated group and matched control group over 2 years.
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showed that long-term oral BCAA supplementation improves
the clinical outcome of advanced liver cirrhosis.[3,32] These trials
found that the EFS, including death due to any cause and
deterioration of liver disease with or without the development of
HCC, improved during oral BCAA supplementation.[3,32] The
current guidelines of the European Society for Clinical Nutrition
andMetabolism recommend taking a BCAA-enriched formula in
case of hepatic encephalopathy during enteral nutrition.[33]
The MELD score is a well-known predictive indicator of the
pretransplant waiting list death rate.[34,35] In the present study,
the MELD score improved signiﬁcantly over time in the patients
who were treated with 12.45 g of BCAAs relative to the control
group (Fig. 3A). The progression of liver cirrhosis can be slowed
by other treatments, such as nucleos(t)ide analogs for treating
chronic hepatitis B (CHB) or abstaining from alcohol. Therefore,
nucleos(t)ide analogs might have inﬂuenced the improvements in
the MELD scores in both of the present study groups. However,
the number of CHB patients with a high viral load (HBV DNA>
2000IU/mL)—and hence being treated with an antiviral agent—
was only slightly higher in the matched control group than in the
patients treated with 12.45g of BCAAs (see Table, supplemental
data, http://links.lww.com/MD/B640 which shows the number of
CHB patients with a high viral load and their treatment). An
Italian randomized, controlled, double-blind multicenter study
found that long-term BCAA supplementation in patients with
liver cirrhosis improved both the serum bilirubin level and CP
score.[3] These results are very similar to those obtained in the
present study. Decreased serum bilirubin levels may lead to
improvements in the MELD score. However, in contrast to the
ﬁndings in a Japanese study, we found no improvement in the
serum albumin level.[32] The albumin level exhibits greater
dynamic changes than the serum bilirubin level in various
situations, including infection, hemorrhage, and poor nutrition.
In the present study, despite the improvement in theMELD score,
there were no signiﬁcant intergroup differences in the EFS. This
might indicate that improvements in the MELD scores have
negligible effects in the presence of major cirrhotic complications.
There were no signiﬁcant differences in hepatic encephalopa-
thy between the 2 groups (Table 4). This might have been due to6minimal hepatic encephalopathy being overlooked owing to the
retrospective design of this study or to the duration of BCAA
supplementation in the present study being shorter than those in
previous studies. About 30% of the patients discontinued BCAA
supplementation within 1 year; thus, the early withdrawal of
BCAA supplementation seems to affect the improvement of
hepatic encephalopathy.[10]
In the subgroup analysis of the entire BCAA group treated with
BCAAs, the CP score did not improve in patients treated with <
12.45g of BCAAs. In patients treated with 4.15g of BCAAs, only
marginal effects were found (Table 3). These observations imply
that optimizing the dose of BCAA supplementation is important
for maximizing the beneﬁcial effects. A large-scale prospective
study is needed for optimizing the dose of BCAA supplementa-
tion in patients with liver cirrhosis.
Few studies have evaluated the anticarcinogenic effects of
BCAAs in patients with liver cirrhosis.[36–38] The anticarcino-
genic effect of BCAA supplementation could be due to
improvements in insulin resistance, whereas its antiangiogenic
effect could be due to the inhibition of the vascular endothelial
growth factor.[9,39,40] A Japanese study found that the incidence
of HCC decreased in speciﬁc populations, such as in patients with
chronic hepatitis C (CHC) or in those with a body mass index
(BMI) of≥25kg/m2. However, the etiology of liver cirrhosis in
Korea differs from that in Japan. In the present study, CHB and
alcoholic liver cirrhosis were more common than CHC. Further,
a subgroup analysis of the effects of a BMI of≥25 kg/m2 could
not be performed owing to the small number of patients.
Our study was subject to several limitations. First, the guideline
for using BCAA supplementation varied among the included
centers. However, after adjustments based on the propensity
scores, differences in the baseline characteristics disappeared
between the 2 study groups. Second, the number of patients
treated with 12.45g of BCAAs was smaller in this study than in
previous studies owing to the high cost or poor palatability of the
particular BCAA granules used. Third, although signiﬁcant
improvements in theMELD scores were demonstrated in patients
treated with BCAAs, there were no improvements in the clinical
outcomes in this study. To improve the clinical outcomes, further
evaluation of the optimal duration and indication of BCAA
supplementation would be needed considering the disease stage
and degree of malnutrition. Fourth, the retrospective design of
this study meant that the follow-up interval varied among
the patients and their dietary habits were not tracked. A further
[19] Austin PC. A critical appraisal of propensity-score matching in the
Park et al. Medicine (2017) 96:24 www.md-journal.comlarge-scale prospective study would be needed to delineate the
efﬁcacy of oral BCAAs and overcome these limitations.
This study has demonstrated that the MELD score improves
during treatment with long-term oral BCAA supplementation in
advanced liver disease. The efﬁcacy of BCAA supplementation
varies with the dosing regimen; thus, it is important to determine
how to maximize the effectiveness of BCAAs in chronic liver
disease.5. Conclusion
Long-term oral BCAA supplementation has beneﬁcial effects on
prognostic markers in patients with advanced liver cirrhosis. A
sufﬁcient dosage of oral BCAA supplementationwould be needed
to increase its beneﬁcial effects.References
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